JP6449308B2 - がんバイオマーカー及びその使用 - Google Patents

がんバイオマーカー及びその使用 Download PDF

Info

Publication number
JP6449308B2
JP6449308B2 JP2016546183A JP2016546183A JP6449308B2 JP 6449308 B2 JP6449308 B2 JP 6449308B2 JP 2016546183 A JP2016546183 A JP 2016546183A JP 2016546183 A JP2016546183 A JP 2016546183A JP 6449308 B2 JP6449308 B2 JP 6449308B2
Authority
JP
Japan
Prior art keywords
her2
specific binding
binding member
cancer
copy number
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016546183A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016533395A5 (cg-RX-API-DMAC10.html
JP2016533395A (ja
Inventor
レオン，キンメイ
スン，ハイジュン
ベイティ，サラ
ローランド，ロバート
Original Assignee
エフ−スター バイオテクノロジー リミテッド
エフ−スター バイオテクノロジー リミテッド
エフ−スター ビオテヒノロジーシュ フォルシュングス− ウント エントヴィックルングスゲス．エム．ベー．ハー．
エフ−スター ビオテヒノロジーシュ フォルシュングス− ウント エントヴィックルングスゲス．エム．ベー．ハー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エフ−スター バイオテクノロジー リミテッド, エフ−スター バイオテクノロジー リミテッド, エフ−スター ビオテヒノロジーシュ フォルシュングス− ウント エントヴィックルングスゲス．エム．ベー．ハー．, エフ−スター ビオテヒノロジーシュ フォルシュングス− ウント エントヴィックルングスゲス．エム．ベー．ハー． filed Critical エフ−スター バイオテクノロジー リミテッド
Publication of JP2016533395A publication Critical patent/JP2016533395A/ja
Publication of JP2016533395A5 publication Critical patent/JP2016533395A5/ja
Application granted granted Critical
Publication of JP6449308B2 publication Critical patent/JP6449308B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2016546183A 2013-10-04 2014-10-03 がんバイオマーカー及びその使用 Expired - Fee Related JP6449308B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1317622.7A GB201317622D0 (en) 2013-10-04 2013-10-04 Cancer biomarkers and uses thereof
GB1317622.7 2013-10-04
PCT/GB2014/052994 WO2015049537A1 (en) 2013-10-04 2014-10-03 Cancer biomarkers and uses thereof

Publications (3)

Publication Number Publication Date
JP2016533395A JP2016533395A (ja) 2016-10-27
JP2016533395A5 JP2016533395A5 (cg-RX-API-DMAC10.html) 2018-08-09
JP6449308B2 true JP6449308B2 (ja) 2019-01-09

Family

ID=49630223

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016546183A Expired - Fee Related JP6449308B2 (ja) 2013-10-04 2014-10-03 がんバイオマーカー及びその使用

Country Status (20)

Country Link
US (1) US20160289336A1 (cg-RX-API-DMAC10.html)
EP (1) EP3052647B1 (cg-RX-API-DMAC10.html)
JP (1) JP6449308B2 (cg-RX-API-DMAC10.html)
KR (1) KR20160092992A (cg-RX-API-DMAC10.html)
CN (1) CN105722997A (cg-RX-API-DMAC10.html)
AU (1) AU2014330942A1 (cg-RX-API-DMAC10.html)
BR (1) BR112016007348A2 (cg-RX-API-DMAC10.html)
CA (1) CA2925186A1 (cg-RX-API-DMAC10.html)
CL (1) CL2016000777A1 (cg-RX-API-DMAC10.html)
DK (1) DK3052647T3 (cg-RX-API-DMAC10.html)
EA (1) EA201690450A1 (cg-RX-API-DMAC10.html)
ES (1) ES2687783T3 (cg-RX-API-DMAC10.html)
GB (1) GB201317622D0 (cg-RX-API-DMAC10.html)
HR (1) HRP20181566T1 (cg-RX-API-DMAC10.html)
IL (1) IL244510A0 (cg-RX-API-DMAC10.html)
LT (1) LT3052647T (cg-RX-API-DMAC10.html)
MX (1) MX2016004286A (cg-RX-API-DMAC10.html)
PE (1) PE20160950A1 (cg-RX-API-DMAC10.html)
SG (1) SG11201602605TA (cg-RX-API-DMAC10.html)
WO (1) WO2015049537A1 (cg-RX-API-DMAC10.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE423140T1 (de) 2005-01-05 2009-03-15 F Star Biotech Forsch & Entw Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
PL3241842T3 (pl) 2007-06-26 2024-06-10 F-Star Therapeutics Limited Prezentacja środków wiążących
EP2113255A1 (en) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
WO2016162505A1 (en) * 2015-04-08 2016-10-13 F-Star Biotechnology Limited Her2 binding agent therapies
WO2017210335A1 (en) 2016-06-01 2017-12-07 Bristol-Myers Squibb Company Imaging methods using 18f-radiolabeled biologics
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
SG11201811184UA (en) 2016-06-20 2019-01-30 F Star Beta Ltd Lag -3 binding members
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
RU2764548C2 (ru) 2016-08-09 2022-01-18 Кимаб Лимитед Анти-icos антитела
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
WO2019122882A1 (en) * 2017-12-19 2019-06-27 Kymab Limited Bispecific antibody for icos and pd-l1
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
CN107868814A (zh) * 2017-12-19 2018-04-03 威海威仕泰医疗科技有限公司 一种用于检测HER2基因的Dig标记探针的制备方法
CR20250022A (es) 2018-04-02 2025-02-25 Bristol Myers Squibb Co Anticuerpos anti-trem-1, ácidos nucleicos y vectores de los mismos (divisional 2020-0450)
CN112584862A (zh) * 2018-05-17 2021-03-30 伊米若梅有限公司 Ch3结构域表位标签
CN108875302B (zh) * 2018-06-22 2022-02-22 广州漫瑞生物信息技术有限公司 一种检测细胞游离肿瘤基因拷贝数变异的系统和方法
GB201811404D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
AU2019301206B2 (en) 2018-07-12 2025-10-30 Invox Pharma Limited Antibody molecules that bind CD137 and OX40
GB201811403D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Antibody molecules
GB201811415D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-Mesothelin Anti bodies
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
GB201811408D0 (en) * 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
BR112021000394A2 (pt) 2018-07-12 2021-04-06 F-Star Beta Limited Moléculas de anticorpo que se ligam a pd-l1 e cd137
GB201811450D0 (en) 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
KR102325731B1 (ko) * 2020-01-15 2021-11-15 주식회사 베르티스 암의 진단용 조성물
MX2024001877A (es) 2021-08-10 2024-02-28 Kymab Ltd Tratamiento de dermatitis atopica.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE423140T1 (de) * 2005-01-05 2009-03-15 F Star Biotech Forsch & Entw Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften
PL3241842T3 (pl) * 2007-06-26 2024-06-10 F-Star Therapeutics Limited Prezentacja środków wiążących
EP2113255A1 (en) * 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
US20120121586A1 (en) * 2009-05-29 2012-05-17 Astrid Kiermaier Modulators for her2 signaling in her2 expressing patients with gastric cancer
EP2407487A1 (en) * 2010-07-14 2012-01-18 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Multispecific modular antibody

Also Published As

Publication number Publication date
CN105722997A (zh) 2016-06-29
PE20160950A1 (es) 2016-10-02
CA2925186A1 (en) 2015-04-09
HK1221746A1 (en) 2017-06-09
AU2014330942A1 (en) 2016-05-19
KR20160092992A (ko) 2016-08-05
SG11201602605TA (en) 2016-04-28
HRP20181566T1 (hr) 2018-11-30
CL2016000777A1 (es) 2017-02-17
MX2016004286A (es) 2017-01-18
GB201317622D0 (en) 2013-11-20
ES2687783T3 (es) 2018-10-29
US20160289336A1 (en) 2016-10-06
BR112016007348A2 (pt) 2018-01-23
LT3052647T (lt) 2018-10-25
DK3052647T3 (en) 2018-10-22
EP3052647B1 (en) 2018-07-11
IL244510A0 (en) 2016-04-21
EP3052647A1 (en) 2016-08-10
WO2015049537A1 (en) 2015-04-09
EA201690450A1 (ru) 2016-10-31
JP2016533395A (ja) 2016-10-27

Similar Documents

Publication Publication Date Title
JP2016533395A (ja) がんバイオマーカー及びその使用
JP6823094B2 (ja) Ｒｏｒ１癌の治療および転移の阻害に使用するための抗体およびワクチン
US8426562B2 (en) Methods and compositions for modulating tumor cell activity
Matsubara et al. Impact of insulin-like growth factor type 1 receptor, epidermal growth factor receptor, and HER2 expressions on outcomes of patients with gastric cancer
JP2020511993A (ja) ＮＲＧ１融合遺伝子を有する細胞の処置における使用のためのＥｒｂＢ−２及びＥｒｂＢ３結合二重特異性抗体
TW201837467A (zh) 用於癌症之診斷及治療方法
TW201642897A (zh) Ｈｅｒ２結合劑治療
KR20130103734A (ko) 바이오마커 및 치료 방법
CN104813168A (zh) 需要pd-l1抑制剂综合疗法的患者的鉴定
JP7763850B2 (ja) ＰＤＧＦＲα阻害剤でがんを治療する方法
JP2022512744A (ja) 肉腫様腎臓がんのための診断および治療方法
JP2015528802A (ja) フコシル化が低い抗ｈｅｒ２抗体を用いた新規治療処置
JP2024071393A (ja) Ｈｅｒ２及びｈｅｒ３陽性癌に罹患している対象を治療するための手段及び方法
JP2025533015A (ja) 薬物抵抗性肝細胞癌の処置
KR20240045281A (ko) Her3 항원 결합 분자를 사용한 암 치료 및 예방
Dedić Plavetić et al. Role of HER2 signaling pathway in breast cancer: biology, detection and therapeutical implications
EP3923985A1 (en) Antibodies to cell adhesion molecule-related/down-regulated by oncogenes (cdon) and uses thereof
US20170306415A1 (en) Predicting tumor responses to antibodies against hepatocyte growth factor (hgf) and/or its cognate receptor, c-met
AU2008308761B2 (en) NLRR-1 antagonists and uses thereof
HK1221746B (en) Cancer biomarkers and uses thereof
Parakh Novel Anti-ErbB Antibodies in the Treatment of Cancer
HK40035028A (en) Therapeutic and diagnostic methods for cancer
HK40021172A (en) Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment of cells that have an nrg1 fusion gene
CN121652272A (zh) Ror1抗体或抗原结合分子

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171002

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171002

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180626

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20180626

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20180628

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180731

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181026

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20181115

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20181205

R150 Certificate of patent or registration of utility model

Ref document number: 6449308

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees
S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350